Stockreport
Biomarin Could Possibly Be The First To Obtain FDA Approval For Hemophilia Gene Therapy Treatment [Seeking Alpha]
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
SummaryBiomarin had its BLA accepted by the FDA for its gene therapy valoctocogene roxaparvovec which is being used to treat patients with severe Hemophilia A.The entire Hemophilia market is estimated to be worth $16.84 billion by 2026, However, Hemophilia A accounts for 80% of all Hemophilia cases.The PDUFA date for FDA review of valoctocogene roxaparvovec for severe Hemophilia A is set for August 21, 2020; For the time being there is no plan for advisory panel.Biomarin has a chance to obtain regulatory approval in Europe for valoctocogene roxaparvovec; The EMA had already accepted the application and is currently under review.BMRNBiologics License Application (BLA) accepted by the FDAAccepted BLA Moves Company Forward In Large MarketThe BLA being accepted for valoctocogene roxaparvovec (valrox) set an FDA first. Another good thing to come out of it would be the first gene therapy to be approved for the treatment of patients with Hemophilia A. Hemophilia A is a Factor VIII (FVIII) de
[Read more]
IMPACT SNAPSHOT | EVENT TIME: | BMRN | ||||
---|---|---|---|---|---|---|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
LAST PRICE | ||
VWAP | ||
High:
|
MAX UP |
High:
|
Low:
|
MAX DOWN |
Low:
|
%
|
POST NEWS RANGE |
%
|
|
PRICE CHANGE |
|
|
PRICE CHANGE PERCENTAGE |
|
|
S&P 500 (SPX) |
|
%
|
VOLUME RATIO |
%
|
VOLUME (SHARES) | ||
TICKS | ||
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
BMRN alerts
BMRN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRN alerts
High impacting BioMarin Pharmaceutical Inc. news events
Weekly update
A roundup of the hottest topics
BMRN
NEWS
NEWS
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Robert W. Baird from an "outperform" rating to a "neutral" rating. They now have a $72.00 price target on the stock, down previously from $104.00.[MarketBeat]
- BioMarin Pharmaceutical to lay off 170 employees [Seeking Alpha][Seeking Alpha]
- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $113.00 price target on the stock.[MarketBeat]
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV [Yahoo! Finance][Yahoo! Finance]
- BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV[PR Newswire]
- More
BMRN
SEC Filings
SEC Filings
- 5/14/24 - Form 8-K
- 5/13/24 - Form 4
- 5/10/24 - Form 144
- BMRN's page on the SEC website
- More